Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder

Psychiatry Research

Volumn 210, Issue 3, 2013, Pages 1299-1300

  Cooper, Alissa J ^a   Narasimhan, Sneha ^a   Rickels, Karl ^a   Lohoff, Falk W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anxiety disorders; Hypothalamic pituitary adrenal axis; Pharmacogenetics

Indexed keywords

VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; NEUROPEPTIDE;

ARTICLE; DRUG EFFICACY; DRUG RESPONSE; GENE; GENERALIZED ANXIETY DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PAC1 GENE; PCAP GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ADULT; ANXIETY DISORDERS; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; GENETICS; MALE; PHARMACOGENETICS; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CYCLOHEXANOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; NEUROPEPTIDES; PHARMACOGENETICS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; POLYMORPHISM, GENETIC; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; TREATMENT OUTCOME;

EID: 84888293966     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.07.038     Document Type: Article

References (8)

1. Baldwin D.S., Nair R.V. Escitalopram in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics 2005, 5:443-449.
2. Hashimoto H., Shintani N., Tanaka K., Mori W., Hirose M., Matsuda T., Sakaue M., Miyazaki J., Niwa H., Tashiro F., Yamamoto K., Koga K., Tomimoto S., Kunugi A., Suetake S., Baba A. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proceedings of National Academy of Sciences United States of America 2001, 98:13355-13360.
3. Koga M., Ishiguro H., Horiuchi Y., Inada T., Ujike H., Itokawa M., Otowa T., Watanabe Y., Someya T., Arinami T. Replication study of association between ADCYAP1 gene polymorphisms and schizophrenia. Psychiatric Genetics 2010, 20:123-125.
4. Kovanen L., Saarikoski S.T., Haukka J., Pirkola S., Aromaa A., Lonnqvist J., Partonen T. Circadian clock gene polymorphisms in alcohol use disorders and alcohol consumption. Alcohol and Alcoholism 2010, 45:303-311.
5. Lohoff F.W., Aquino T.D., Narasimhan S., Multani P.K., Etemad B., Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics Journal 2011.
6. Otto C., Martin M., Wolfer D.P., Lipp H.P., Maldonado R., Schutz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Molecular Brain Research 2001, 92:78-84.
7. Ressler K.J., Mercer K.B., Bradley B., Jovanovic T., Mahan A., Kerley K., Norrholm S.D., Kilaru V., Smith A.K., Myers A.J., Ramirez M., Engel A., Hammack S.E., Toufexis D., Braas K.M., Binder E.B., May V. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011, 470:492-497.
8. Rickels K., Montgomery S.A., Tourian K.A., Guelfi J.D., Pitrosky B., Padmanabhan S.K., Germain J.M., Leurent C., Brisard C. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. Journal of Clinical Psychopharmacology 2010, 30:18-24.